Correction to: Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-023-01478-5, published online 14 July 2023
After online publication of the article, the authors noticed one inadvertent mistake in Fig. 4f. The image of BICC1 IHC in the BICC1+LCN2 ab group was repeatedly inserted as the image of BICC1+CXCL1 ab group by mistake during the final revision process. The correct figure was provided as follows. The correction did not affect any of our results or discussion as present in the original publication. We apologize for this inadvertent mistake.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Huang, C., Li, H., Xu, Y. et al. Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Sig Transduct Target Ther 9, 8 (2024). https://doi.org/10.1038/s41392-023-01721-z
Published:
DOI: https://doi.org/10.1038/s41392-023-01721-z
